Surgery, Radiation, and Temozolomide in a Rare Pituitary Cancer
Original title: Role of Surgery in the Multimodal Treatment of Pituitary Carcinoma: A Retrospective Single-Institution Case Series.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
These treatments are already used by doctors, but this was only a look back at past patient records, not a trial.
The short version
Everyone in this study who lived at least five years after their pituitary cancer diagnosis had been treated with the drug temozolomide.
What was studied. Doctors looked back at the records of 20 patients treated for pituitary carcinoma at one cancer center between 1993 and 2023. Pituitary carcinoma is a rare tumor of the pituitary gland that can spread to other parts of the body. The doctors reviewed the surgeries, the other treatments, and how long people lived.
What they found. The 20 patients had 102 brain and skull surgeries in all. In 13 patients the tumor turned aggressive more than five years after the first surgery, while in 7 patients it spread within the first five years. Everyone who lived at least five years after the cancer diagnosis had received temozolomide, and most had radiation too.
What this means, and what it doesn't
What it could mean: Using several treatments together may help people with this rare cancer live longer. It may be worth asking your care team whether a plan that combines surgery, radiation, and temozolomide fits your situation.
What it doesn't mean: This does not mean a new treatment was found. It was a look back at the records of 20 people at a single hospital, not a trial. That kind of study cannot prove the treatments are what made people live longer. It is not a cure, and it does not promise any one person more time.
Source: PubMed, June 25, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.